Gary C Chamness
Overview
Explore the profile of Gary C Chamness including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
2563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, et al.
Proc Natl Acad Sci U S A
. 2019 Dec;
116(52):26823-26834.
PMID: 31826955
Forkhead box A1 (FOXA1) is a pioneer factor that facilitates chromatin binding and function of lineage-specific and oncogenic transcription factors. Hyperactive FOXA1 signaling due to gene amplification or overexpression has...
2.
Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, et al.
Mol Cancer Res
. 2019 Aug;
17(11):2318-2330.
PMID: 31420371
Despite effective strategies, resistance in HER2 breast cancer remains a challenge. While the mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2 models, its potential...
3.
Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo M, et al.
Br J Cancer
. 2018 Dec;
120(3):331-339.
PMID: 30555156
Background: The oestrogen receptor (ER) is an important therapeutic target in ER-positive (ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but...
4.
Xu X, De Angelis C, Burke K, Nardone A, Hu H, Qin L, et al.
Clin Cancer Res
. 2017 May;
23(17):5123-5134.
PMID: 28487443
Resistance to anti-HER2 therapies in HER2 breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant...
5.
Giuliano M, Hu H, Wang Y, Fu X, Nardone A, Herrera S, et al.
Clin Cancer Res
. 2015 May;
21(17):3995-4003.
PMID: 26015514
Purpose: To investigate the direct effect and therapeutic consequences of epidermal growth factor receptor 2 (HER2)-targeting therapy on expression of estrogen receptor (ER) and Bcl2 in preclinical models and clinical...
6.
Suo J, Medina D, Herrera S, Zheng Z, Jin L, Chamness G, et al.
Cell Biosci
. 2015 Mar;
5:10.
PMID: 25774287
Background: The INT6 gene was first discovered as a site of integration in mouse mammary tumors by the mouse mammary tumor virus; however, INT6's role in the development of human...
7.
Veeraraghavan J, Tan Y, Cao X, Kim J, Wang X, Chamness G, et al.
Nat Commun
. 2014 Aug;
5:4577.
PMID: 25099679
Characterizing the genetic alterations leading to the more aggressive forms of oestrogen receptor-positive (ER+) breast cancers is of critical significance in breast cancer management. Here we identify recurrent rearrangements between...
8.
Wang Y, Morrison G, Gillihan R, Guo J, Ward R, Fu X, et al.
Breast Cancer Res
. 2011 Nov;
13(6):R121.
PMID: 22123186
Introduction: The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent. Here we...
9.
Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington K, et al.
J Natl Cancer Inst
. 2011 Mar;
103(7):538-52.
PMID: 21447808
Background: Estrogen receptor (ER) α is a successful therapeutic target in breast cancer, but patients eventually develop resistance to antiestrogens such as tamoxifen. Methods: To identify genes whose expression was...
10.
Dave B, Migliaccio I, Gutierrez M, Wu M, Chamness G, Wong H, et al.
J Clin Oncol
. 2010 Dec;
29(2):166-73.
PMID: 21135276
Purpose: Phosphatase and tensin homolog (PTEN) loss or activating mutations of phosphoinositol-3 (PI3) kinase (PIK3CA) may be associated with trastuzumab resistance. Trastuzumab, the humanized human epidermal growth factor receptor 2...